The clinical relevance of OSM in inflammatory diseases: a comprehensive review
Oncostatin M (OSM) is a pleiotropic cytokine involved in a variety of inflammatory responses such as wound healing, liver regeneration, and bone remodeling. As a member of the interleukin-6 (IL-6) family of cytokines, OSM binds the shared receptor gp130, recruits either OSMRβ or LIFRβ, and activates...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1239732/full |
| _version_ | 1797670733400244224 |
|---|---|
| author | Cody L. Wolf Clyde Pruett Darren Lighter Cheryl L. Jorcyk Cheryl L. Jorcyk |
| author_facet | Cody L. Wolf Clyde Pruett Darren Lighter Cheryl L. Jorcyk Cheryl L. Jorcyk |
| author_sort | Cody L. Wolf |
| collection | DOAJ |
| description | Oncostatin M (OSM) is a pleiotropic cytokine involved in a variety of inflammatory responses such as wound healing, liver regeneration, and bone remodeling. As a member of the interleukin-6 (IL-6) family of cytokines, OSM binds the shared receptor gp130, recruits either OSMRβ or LIFRβ, and activates a variety of signaling pathways including the JAK/STAT, MAPK, JNK, and PI3K/AKT pathways. Since its discovery in 1986, OSM has been identified as a significant contributor to a multitude of inflammatory diseases, including arthritis, inflammatory bowel disease, lung and skin disease, cardiovascular disease, and most recently, COVID-19. Additionally, OSM has also been extensively studied in the context of several cancer types including breast, cervical, ovarian, testicular, colon and gastrointestinal, brain,lung, skin, as well as other cancers. While OSM has been recognized as a significant contributor for each of these diseases, and studies have shown OSM inhibition is effective at treating or reducing symptoms, very few therapeutics have succeeded into clinical trials, and none have yet been approved by the FDA for treatment. In this review, we outline the role OSM plays in a variety of inflammatory diseases, including cancer, and outline the previous and current strategies for developing an inhibitor for OSM signaling. |
| first_indexed | 2024-03-11T21:03:52Z |
| format | Article |
| id | doaj.art-a58efacfd577425cbf43de615390c1da |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-11T21:03:52Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-a58efacfd577425cbf43de615390c1da2023-09-29T15:50:13ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-09-011410.3389/fimmu.2023.12397321239732The clinical relevance of OSM in inflammatory diseases: a comprehensive reviewCody L. Wolf0Clyde Pruett1Darren Lighter2Cheryl L. Jorcyk3Cheryl L. Jorcyk4Department of Biomolecular Sciences, Boise State University, Boise, ID, United StatesDepartment of Biological Sciences, Boise State University, Boise, ID, United StatesDepartment of Biological Sciences, Boise State University, Boise, ID, United StatesDepartment of Biomolecular Sciences, Boise State University, Boise, ID, United StatesDepartment of Biological Sciences, Boise State University, Boise, ID, United StatesOncostatin M (OSM) is a pleiotropic cytokine involved in a variety of inflammatory responses such as wound healing, liver regeneration, and bone remodeling. As a member of the interleukin-6 (IL-6) family of cytokines, OSM binds the shared receptor gp130, recruits either OSMRβ or LIFRβ, and activates a variety of signaling pathways including the JAK/STAT, MAPK, JNK, and PI3K/AKT pathways. Since its discovery in 1986, OSM has been identified as a significant contributor to a multitude of inflammatory diseases, including arthritis, inflammatory bowel disease, lung and skin disease, cardiovascular disease, and most recently, COVID-19. Additionally, OSM has also been extensively studied in the context of several cancer types including breast, cervical, ovarian, testicular, colon and gastrointestinal, brain,lung, skin, as well as other cancers. While OSM has been recognized as a significant contributor for each of these diseases, and studies have shown OSM inhibition is effective at treating or reducing symptoms, very few therapeutics have succeeded into clinical trials, and none have yet been approved by the FDA for treatment. In this review, we outline the role OSM plays in a variety of inflammatory diseases, including cancer, and outline the previous and current strategies for developing an inhibitor for OSM signaling.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1239732/fulloncostatin M (OSM)oncostatin M receptor beta (OSMRβ)inflammatory diseasescytokinecancermetastasis |
| spellingShingle | Cody L. Wolf Clyde Pruett Darren Lighter Cheryl L. Jorcyk Cheryl L. Jorcyk The clinical relevance of OSM in inflammatory diseases: a comprehensive review Frontiers in Immunology oncostatin M (OSM) oncostatin M receptor beta (OSMRβ) inflammatory diseases cytokine cancer metastasis |
| title | The clinical relevance of OSM in inflammatory diseases: a comprehensive review |
| title_full | The clinical relevance of OSM in inflammatory diseases: a comprehensive review |
| title_fullStr | The clinical relevance of OSM in inflammatory diseases: a comprehensive review |
| title_full_unstemmed | The clinical relevance of OSM in inflammatory diseases: a comprehensive review |
| title_short | The clinical relevance of OSM in inflammatory diseases: a comprehensive review |
| title_sort | clinical relevance of osm in inflammatory diseases a comprehensive review |
| topic | oncostatin M (OSM) oncostatin M receptor beta (OSMRβ) inflammatory diseases cytokine cancer metastasis |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1239732/full |
| work_keys_str_mv | AT codylwolf theclinicalrelevanceofosmininflammatorydiseasesacomprehensivereview AT clydepruett theclinicalrelevanceofosmininflammatorydiseasesacomprehensivereview AT darrenlighter theclinicalrelevanceofosmininflammatorydiseasesacomprehensivereview AT cherylljorcyk theclinicalrelevanceofosmininflammatorydiseasesacomprehensivereview AT cherylljorcyk theclinicalrelevanceofosmininflammatorydiseasesacomprehensivereview AT codylwolf clinicalrelevanceofosmininflammatorydiseasesacomprehensivereview AT clydepruett clinicalrelevanceofosmininflammatorydiseasesacomprehensivereview AT darrenlighter clinicalrelevanceofosmininflammatorydiseasesacomprehensivereview AT cherylljorcyk clinicalrelevanceofosmininflammatorydiseasesacomprehensivereview AT cherylljorcyk clinicalrelevanceofosmininflammatorydiseasesacomprehensivereview |